2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-161266
    COX-2/NLRP3-IN-1 3057274-61-7 98%
    COX-2/NLRP3-IN-1 (Compound 6k) is a COX-2/NLRP3 inhibitor with a IC50 of 1.53 μM for COX-2. COX-2/NLRP3-IN-1 exerts anti-inflammatory effects by inhibiting the NF-κB/NLRP3 signaling pathway.
    COX-2/NLRP3-IN-1
  • HY-161315
    15-LOX-IN-1 98%
    15-LOX-IN-1 (Compound 7c) is a 15-LOX inhibitor with a IC50 value of 1.92 μM. 15-LOX-IN-1 has anti-inflammatory activity.
    15-LOX-IN-1
  • HY-161329
    NLRP3-IN-32 98%
    NLRP3-IN-32 (compound 7a), a 3, 4-dihydronaphthalene-1(2H)-one derivative, is a potential NLRP3 inflammatory vesicles inhibitor. NLRP3-IN-32 can block the assembly and activation of NLRP3 inflammasome by down-regulating the expression of NLPR3 and apoptosis-associated speck-like protein containing a CARD (ASC), and inhibiting the production of reactive oxygen species (ROS) and other inflammatory mediators. NLRP3-IN-32 inhibits the phosphorylation of IκBα and NF-κB/p65 and the nuclear translocation of p65, thereby inhibiting NF-κB signaling.
    NLRP3-IN-32
  • HY-161333
    ADS031 98%
    ADS031, a histamine H3R antagonist, displays 12.5 nM affinity at the hH3R and the highest inhibitory activity against AChE (IC50 = 1.537 μM).
    ADS031
  • HY-161342
    CTSL/CAPN1-IN-2 2410075-64-6 98%
    CTSL/CAPN1-IN-2 (Compound 14b) is an orally active inhibitor of both CTSL and CAPN1, with IC50 values of 6.88 nM and 347.6 nM, respectively. CTSL/CAPN1-IN-2 possesses anti-inflammatory properties and favorable pharmacokinetic characteristics. CTSL/CAPN1-IN-2 exhibits broad-spectrum antiviral activity against coronaviruses by blocking viral entry.
    CTSL/CAPN1-IN-2
  • HY-161349
    LTA4H-IN-4 3034839-03-4 98%
    LTA4H-IN-4 (compound 3) is an orally active LTA4H inhibitor. The IC50 value of LTA4H-IN-4 for hERG is 156 μM. LTA4H-IN-4 can be used in inflammation related studies.
    LTA4H-IN-4
  • HY-161354
    JAK3 covalent inhibitor-2 2664050-97-7 98%
    JAK3 covalent inhibitor-2 (compound J1b) is a selective, orally potent JAK3 inhibitor (IC50=7.2 nM) with low toxicity, anti-inflammatory activity and good bioavailability.
    JAK3 covalent inhibitor-2
  • HY-161364
    Antibacterial agent 200 98%
    Antibacterial agent 200 (pyridyl HH 7), a unique hydrazyl hydroxycoumarin (HH), has strong antibacterial efficacy and broad antibacterial spectrum with MIC values ranging from 0.5 to 32 μg/mL for Gram-positive and Gram-negative bacteria. Antibacterial agent 200 exhibits a good inhibition against Pseudomonas aeruginosa 27853 with a low MIC value of 0.5 μg/mL. Antibacterial agent 200 can eradicate the integrity of bacterial membrane, result in the leakage of intracellular proteins, and interact with bacterial DNA gyrase via non-covalent binding.
    Antibacterial agent 200
  • HY-161381
    PDE4-IN-15 3034837-89-0 98%
    PDE4-IN-15 (compound 7b-1) is an inhibitor of PDE4 (IC50 = 0.17 μM) and has anti-TNF-α activity (EC50 = 0.19 μM). PDE4-IN-15 has a good skin permeability.
    PDE4-IN-15
  • HY-161390
    SPC-alkyne 98%
    SPC-alkyne (compound 9) is an alkynyl derivative. SPC-alkyne suppresses IL-2 production and AP-1 and NFAT reporters.
    SPC-alkyne
  • HY-161396
    Anti-inflammatory agent 76 98%
    Anti-inflammatory agent 76 (Compd 8b), an anti-inflammatory agent, exhibits good NO, IL-1β and IL-6 inhibitory activities.
    Anti-inflammatory agent 76
  • HY-161397
    NA-1-157 98%
    NA-1-157 is a potent irreversible covalent inhibitor of the GES-5 carbapenemase, with a MIC of 0.5 μg/mL.
    NA-1-157
  • HY-161413
    Antibacterial agent 204 1211465-32-5 98%
    Antibacterial agent 204 (Compd P2-56-3) possesses potentiated Rifampin (RIF) activity against Acinetobacter baumannii and Klebsiella pneumoniae. Antibacterial agent 204 (Compd P2-56-3) disrupts the outer membrane of A. baumannii. T.
    Antibacterial agent 204
  • HY-161441
    SIK-IN-2 3033846-20-4 98%
    SIK-IN-2 (Compound 45) is an inhibitor for salt-inducible kinase (SIK), which inhibits SKI1, SIK2 and SIK3 with IC50s of 0.1, 0.2 and 0.4 nM, respectively. SIK-IN-2 inhibits the release of TNFa with IC50 of 0.5 nM, stimulates the LPS (HY-D1056) -induced IL-10 release with EC50 of 2 nM in human macrophages.
    SIK-IN-2
  • HY-161442
    SIK-IN-3 3033845-49-4 98%
    SIK-IN-3 (Compound 6B) is an inhibitor for salt-inducible kinase (SIK), which inhibits SKI1, SIK2 and SIK3 with IC50s of 0.1, 0.3 and 0.8 nM, respectively. SIK-IN-1 inhibits the release of TNFa with IC50 of 0.6 nM, stimulates the LPS (HY-D1056) -induced IL-10 release with EC50 of 3 nM in human macrophages.
    SIK-IN-3
  • HY-161455
    Xanthine oxidase-IN-13 98%
    Xanthine oxidase-IN-13 (Compound 10) is a selective xanthine oxidase inhibitor (IC50: 149.56 μM for bovine xanthine oxidase). Xanthine oxidase-IN-13 can be used for research of inflammatory arthritis.
    Xanthine oxidase-IN-13
  • HY-161465
    HDAC8-IN-7 98%
    HDAC8-IN-7 (H7E), a HDAC8 inhibitor, exerts retinoprotective effects against glaucomatous injury via ameliorating aberrant Müller glia activation and oxidative stress. HDAC8-IN-7 alleviates functional and structural defects within the inner retina.
    HDAC8-IN-7
  • HY-161471
    DCLK1-IN-5 3028774-14-0 98%
    DCLK1-IN-5 (Compound a24) is a DCLK1 inhibitor (IC50: 179.7 nM). DCLK1-IN-5 inhibits lipopolysaccharide (HY-D1056)-induced inflammation via inhibiting DCLK1-mediated IKKβ phosphorylation. DCLK1-IN-5 protects mice against inflammation-induced lung injury and sepsis.
    DCLK1-IN-5
  • HY-161478
    Phosphoserine/BSA 98%
    Phosphoserine/BSA is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    Phosphoserine/BSA
  • HY-161479
    Melamine/OVA 98%
    Melamine/OVA is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    Melamine/OVA
Cat. No. Product Name / Synonyms Application Reactivity